SCHEMBL10088904

SCHEMBL10088904

O=CC1=Cc2c(F)cc(OCc3ccc(C(F)(F)F)cc3C(F)(F)F)cc2OC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 1/20 0.37
SLC6A4 P31645 1/20 0.35
ESRRA P11474 4/20 0.34
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34
SRD5A2 P31213 1/20 0.34
FFAR1 O14842 1/20 0.32
IDO1 P14902 1/20 0.32
ALOX5 P09917 1/20 0.32
FOXM1 Q08050 1/20 0.31
S1PR1 P21453 1/20 0.31
PRKX P51817 1/20 0.31
IKBKE Q14164 1/20 0.31
S1PR5 Q9H228 1/20 0.31
TACR1 P25103 1/20 0.31
PTGES O14684 1/20 0.31
AR P10275 1/20 0.31
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
POLQ O75417 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10088577 0.89 SLC6A4 (0.34) SLC6A4FFAR1ALOX5ARPOLQ
SCHEMBL10088465 0.89 SRD5A1 (0.31) SRD5A1AR
SCHEMBL10088901 0.89 SRD5A1 (0.42) SRD5A1SLC6A4ESRRAMAOAMAOB
SCHEMBL10310541 0.89 EPHX2 (0.36) FFAR1FOXM1ARMAPT
SCHEMBL10088936 0.88 ESRRA (0.41) SRD5A1SLC6A4ESRRAMAOAMAOB
SCHEMBL10088640 0.87 PTGER4 (0.36) MAOBALOX5S1PR1AR
SCHEMBL10088581 0.86 AR (0.34) MAOAMAOBALOX5AR
SCHEMBL10088583 0.85 FFAR4 (0.30)
SCHEMBL10088534 0.85 MAOA (0.31) SRD5A1MAOAMAOBS1PR1
SCHEMBL2326732 0.84 SRD5A1 (0.42) SRD5A1SLC6A4ESRRAMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
WO-2010064707-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF アステラス製薬株式会社 (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 SRD5A1 397/4885SLC6A4 2336/4885ESRRA 645/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 SRD5A1 494/4885SLC6A4 2561/4885ESRRA 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.